The Hollings Cancer Center (HCC) is directed by Andrew S. Kraft, MD with the assistance of a senior leadership team, and together they represent the strong functional nexus of this matrix-based Center. The team is comprised of eight associate directors, each of whom has outstanding expertise in their area of responsibility. They are: Anthony J. Alberg, PhD, MPH, Associate Director of Cancer Control; Marvella E. Ford, PhD, Associate Director of Cancer Disparities; Anita L. Harrison, MPA, Associate Director of Administration; Philip H. Howe, PhD, Associate Director of Basic Sciences; Michael B. Lilly, MD, Associate Director of Translational Research; Steven A. Rosenzweig, PhD, Associate Director of Shared Resources; Melanie B. Thomas, MD, Associate Director of Clinical Investigations; Dennis K. Watson, PhD, Associate Director of Education & Training; and Kevin F. Staveley-O'Carroll, MD, PhD, Medical Director of the HCC Clinical Service Line. The HCC senior leadership team meets once a month as a formal Executive Council, one-on-one with the Director at least monthly, and more frequently with each other and the Director in the context of various HCC board/committee meetings. They provide direct counsel and recommendations to the Director based on these interactions. All final authority for decisions on behalf of the HCC resides with the Director. Dr. Kraft has charged the senior leadership with employing consensus-building techniques as they work directly with the program leaders, shared resource directors, and various HCC boards and committees in formulating center-wide priorities, strategies, and allocation of resources. They work together as a team to ensure consistency in the mission, vision, and goals of the Center and develop synergistic interactions among the basic, translational, and clinical elements of the Center. They provide feedback on the growth of the HCC in their area of responsibility, which is particularly important given the rapid growth of the HCC, and evolving research directions at the national level. Based on this, they plan and implement proactive, integrative approaches for development of the research base, resources, and a formal strategic plan. The consistency of vision is particularly important in effectively leveraging all available resources at MUSC and at the state and national levels and engagement of the community in outreach activities.

Public Health Relevance

Support is requested for the senior leadership of the Hollings Cancer Center. This leadership is critical to ensuring the overall success of the Center in meeting its mission and goals and in the strategic planning and evaluation of all Center efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-09
Application #
9248293
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2017-04-01
Project End
2019-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
9
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Rosenzweig, Steven A (2018) Acquired Resistance to Drugs Targeting Tyrosine Kinases. Adv Cancer Res 138:71-98
Min, Kyung-Won; Zealy, Richard W; Davila, Sylvia et al. (2018) Profiling of m6A RNA modifications identified an age-associated regulation of AGO2 mRNA stability. Aging Cell 17:e12753
Alawieh, Ali; Langley, E Farris; Weber, Shannon et al. (2018) Identifying the role of complement in triggering neuroinflammation after traumatic brain injury. J Neurosci :
Helke, Kristi; Angel, Peggi; Lu, Ping et al. (2018) Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Sci Rep 8:1627
Metelli, Alessandra; Salem, Mohammad; Wallace, Caroline H et al. (2018) Immunoregulatory functions and the therapeutic implications of GARP-TGF-? in inflammation and cancer. J Hematol Oncol 11:24
Scheffel, Matthew J; Scurti, Gina; Wyatt, Megan M et al. (2018) N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunol Immunother 67:691-702
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Schutt, Steven D; Wu, Yongxia; Tang, Chih-Hang Anthony et al. (2018) Inhibition of the IRE-1?/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Adv 2:414-427
Zunke, Friederike; Moise, Alexandra C; Belur, Nandkishore R et al. (2018) Reversible Conformational Conversion of ?-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron 97:92-107.e10

Showing the most recent 10 out of 536 publications